Status:
TERMINATED
A 1-Year Study On The Effects Of CP-945,598 For The Treatment Of Obesity In Overweight Type 2 Diabetic Patients
Lead Sponsor:
Pfizer
Conditions:
Obesity
Eligibility:
All Genders
18-70 years
Phase:
PHASE3
Brief Summary
The purpose of this study is to determine if CP-945,598 is effective in the treatment of obesity in type 2 diabetic patients.
Detailed Description
The CP-945,598 program was terminated on November 3, 2008 due to changing regulatory perspectives on the risk/benefit profile of the CB1 class and likely new regulatory requirements for approval. No s...
Eligibility Criteria
Inclusion
- Subjects must be overweight (BMI 27- 50 kg/m2)
- Subjects must have type 2 diabetes mellitus
Exclusion
- Pregnancy
- Serious or unstable current or past medical conditions
Key Trial Info
Start Date :
November 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 1 2009
Estimated Enrollment :
975 Patients enrolled
Trial Details
Trial ID
NCT00391196
Start Date
November 1 2006
End Date
January 1 2009
Last Update
November 7 2012
Active Locations (91)
Enter a location and click search to find clinical trials sorted by distance.
1
Pfizer Investigational Site
Birmingham, Alabama, United States, 35233
2
Pfizer Investigational Site
Birmingham, Alabama, United States, 35294
3
Pfizer Investigational Site
Huntsville, Alabama, United States, 35801
4
Pfizer Investigational Site
Mobile, Alabama, United States, 36608